Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male Participants

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Healthy Participants

Treatments: Drug: BMS-986256; Drug: Milk of magnesia

Study type: Interventional

Funder types: Industry

Identifiers

NCT04269356

IM026-023

Details and patient eligibility

About

The purpose of this study is to assess the way the body absorbs, distributes, breaks down and eliminates radioactive BMS-986856 in healthy males.

Full description

Recruitment temporarily on hold due to COVID-19.

Enrollment: 8 patients

Sex: Male

Ages: 18 to 55 years old

Volunteers: Accepts Healthy Volunteers

Inclusion and exclusion criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Healthy participants, as determined by no clinically significant deviations from normal in medical history, physical examination abnormalities that would compromise the ability to participate, complete, and/or interpret the results of the study, 12-lead electrocardiograms (ECGs), vital signs, and clinical laboratory results.
• Males must agree to follow specific methods of contraception, if applicable, while participating in the trial

Exclusion Criteria:

• Any significant acute or chronic medical condition that presents a potential risk to the participant and/or that may compromise the objectives of the study
• History of any significant drug and/or food allergies

Other protocol-defined inclusion/exclusion criteria apply

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

BMS-986256

Experimental group

Treatment:

Drug: BMS-986256

Drug: Milk of magnesia